Analysis of the primary endpoint AKI within 72 h after surgery unexpectedly showed a clear trend towards higher AKI rate with RMC-035, attributed to a higher incidence of non-persistent mild AKI (stage 1).
← all excerpts
Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial.
1
—
—